This condition results in hypophosphatemia, which can lead to osteomalacia, manifesting as progressive muscle weakness, bone pain, and fractures.[40,41] In addition to FGF23 levels, tubular reabsorption of phosphate and the ratio of tubular maximum reabsorption of phosphate (TmP/GFR) are crucial for the diagnosing PMT and distinguishing between reduced phosphate absorption and renal phosphate loss – key factors that are currently lacking in our case. The gene discussed is FGF23; the disease is hypophosphatemia.